RSSDI Haryana State Chapter

24/09/2020

Prof. Dr K C Malhotra: My heartfelt condolences on the sad demise of our reverend teacher, guide, philosopher from PGIMS Rohtak. RIP.

28/04/2016

हरियाणा डायबिटीज़ एसोसिएशन के प्रधान डॉ अशोक तनेजा ने कहा कि मधुमेह एक घातक बीमारी है, यदि रक्त में शक्कर की मात्रा को लम्बे समय तक नियंत्रित नहीं किया जाए तो हार्ट अटैक, किडनी फेलियर और ब्रेन अटैक होने की सम्भावना बहुत अधिक हो जाती हैं। डॉ अशोक तनेजा ओरछा, झाँसी में आयोजित एक डायबीटिज सम्मेलन में एक…

18/12/2015

Diabetografia 2

19/11/2015

06/11/2015

28/07/2015

RSSDI Haryana State meet at Gurgaon on 27-07-2015

17/05/2015

Diabetes Drug..Sitagliptin... May Curb Heart Attack Risk In HIV Patients

Researchers: Kevin Yarasheski

In patients infected by human immunodeficiency virus (HIV), a diabetes drug may have benefits which go beyond lowering blood sugar.

Researchers have found that the medicine also works to reduce heart disease and stroke risk in HIV patients.

People with HIV have an elevated risk of heart attacks and diabetes, and problems with glucose, insulin and cholesterol. Part of what drives that risk is chronic inflammation.

In the new study, the researchers found that the diabetes drug sitagliptin (brand name Januvia) both improved metabolism and reduced inflammation in HIV-positive adults taking antiretroviral therapy.

According to principal investigator Kevin Yarasheski, professor of medicine at Washington University School of Medicine in St. Louis"With sitagliptin, sugar levels fell, and several markers of immune activation and inflammation were reduced, indicating the drug may provide long-term benefits for these patients' hearts, bones and livers,"

The study involved 36 HIV patients, aged 18-65, who were on antiretroviral therapy and whose immune status was stable.

At the start of the study, the researchers measured the participants' glucose levels, insulin sensitivity, lipid levels, immune cell counts, several markers of inflammation and other indicators of health.

Half of the study participants then took sitagliptin for eight weeks, and the others received a placebo. Meanwhile, everyone in the study continued with antiretroviral therapy.

"Researchers wanted to know whether this drug would improve patients' blood-sugar problems and reduce the immune markers that we believe are indicators that something is activating the immune system and causing inflammation," and This is what they found.
There findings were also published in he Journal of Clinical Endocrinology & Metabolism.

28/04/2015

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a cloud

13/04/2015

Diet: What to take & what not to take..

13/04/2015

Dr Ashok Taneja presented at Diabetes India at Chennai on Sunday 12th April 2015